Exceptional Response to Short-course 177 Lu-PSMA Radioligand Therapy in a Patient With Metastatic Hormone-sensitive Prostate Cancer.
A 69-year-old man with metastatic hormone-sensitive prostate cancer achieved a significant reduction in PSA levels after treatment with goserelin and 177 Lu-PSMA therapy, but further research is needed to confirm these findings.
Where it sits
this study against the rest of the goserelin corpusSummary and findings
A 69-year-old man with high-volume metastatic hormone-sensitive prostate cancer was treated with goserelin, abiraterone, and cyproterone acetate, reducing PSA from 433.75 ng/mL to 44.29 ng/mL. He then received 3 cycles of 177 Lu-PSMA radioligand therapy, resulting in a near-complete biochemical response with PSA at 0.15 ng/mL. Nine-month follow-up showed complete regression of metastatic lesions.
Abstract
We report a 69-year-old man with de novo high-volume metastatic hormone-sensitive prostate cancer (mHSPC) presenting with PSA 433.75 ng/mL and widespread skeletal and nodal metastases. Androgen-deprivation therapy with goserelin, abiraterone, and cyproterone acetate reduced PSA to 44.29 ng/mL. He subsequently received 3 cycles of 177 Lu-PSMA radioligand therapy, achieving a near-complete biochemical response (PSA 0.15 ng/mL) and resolution of bone pain. Nine-month follow-up 99m Tc-PSMA demonstrated complete regression of metastatic lesions. This case highlights the potential efficacy and safety of early 177 Lu-PSMA therapy in high-volume mHSPC, suggesting a role for optimizing hormonal therapy outcomes.
Background
This paper addresses the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and the potential role of 177 Lu-PSMA radioligand therapy in this context. Prior knowledge indicates that androgen-deprivation therapy is a standard approach for mHSPC, but the efficacy of combining it with radioligand therapy in early treatment stages is less understood. This case report aims to contribute to the understanding of treatment efficacy and safety in high-volume mHSPC.
Methods
The study describes a case of a 69-year-old male with de novo high-volume mHSPC. The patient was treated with goserelin, abiraterone, and cyproterone acetate, followed by 3 cycles of 177 Lu-PSMA radioligand therapy. The primary outcome measure was the change in PSA levels, with follow-up imaging to assess metastatic lesions.
Results
The primary endpoint showed a reduction in PSA from 433.75 ng/mL to 0.15 ng/mL after treatment with 177 Lu-PSMA therapy. The follow-up imaging at 9 months demonstrated complete regression of metastatic lesions. No p-values or confidence intervals were reported.
Interpretation
The findings suggest a significant reduction in PSA levels and regression of metastatic lesions, but the clinical significance of such findings must be evaluated against existing literature. While the results are promising, the small sample size and lack of controlled comparison limit the conclusions that can be drawn. This case highlights the need for further studies to validate the efficacy of 177 Lu-PSMA therapy in mHSPC.
Key findings
- PSA reduced from 433.75 ng/mL to 44.29 ng/mL after androgen-deprivation therapy.
- PSA achieved 0.15 ng/mL after 3 cycles of 177 Lu-PSMA therapy.
- Complete regression of metastatic lesions observed at 9-month follow-up.
Limitations
- Single case report, limiting generalizability.
- No control group for comparison.
- Short follow-up duration of 9 months.